This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the recent data from the phase 2 IGNAZ clinical trial of Felzartamab in patients with IgAN
Ticker(s): BIIBWho's the expert?
Institution: University of Iowa
- Clinical Professor of Internal Medicine - Nephrology, and Medical Director for dialysis at University of Iowa
- Clinical work involves all aspects of care for patients with kidney diseases (including transplant, kidney stones, general nephrology and dialysis) both in an inpatient and outpatient setting
- Teaching role involves formal/class and bedside/clinical education for students, residents of different specialties, nephrology fellows as well as peers.
Interview GoalTo discuss the current treatment landscape and the potential of Felzartamab, a therapy being developed by Biogen for the treatment of IgAN.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
